PredictImmune’s IBD Test Soon Will Be Available in US, Canada, Across French-speaking Europe

PredictImmune’s IBD Test Soon Will Be Available in US, Canada, Across French-speaking Europe
0
(0)

Following product launches in the United Kingdom (UK) and Ireland earlier this year, the developer of the first validated test for inflammatory bowel disease (IBD) now has reached commercialization agreements in the U.S. and Canada, and across French-speaking Europe.

That developer, PredictImmune, is partnering exclusively in North America with KSL Biomedical (KSL) to bring to market the pioneering prognostic biomarker test PredictSURE IBD. The pact calls for KSL to commercialize the product and fulfill orders, and to receive and process samples through its molecular testing lab.

PredictImmune called the agreement — marking its first launch outside the UK — a “significant milestone” in its quest to make the assay available globally. PredictSURE IBD is expected to be available in North America by the first quarter of next year.

“PredictSURE IBD is a major step towards personalized medicine in IBD and we are delighted that, via  our partnership with KSL, patients across North America will now have access to this prognostic tool to enable informed treatment decisions to be made at the point of diagnosis,” Paul Kinnon, PredictImmune CEO, said in a press release.

“This is an exciting test, serving unmet needs on several levels,” said Long Shen, KSL’s chief scientific officer.

“Gastroenterologists want the best assessment of prognosis to inform their choice of treatment and deliver patient benefits, driven by an improved understanding of the implications of diagnosis and more effective implementation of the best therapy. All while lowering the cost of treatment. It’s a win-win-win,” Shen said.

KSL focuses on advancing genomic and proteomic translational medicine for therapeutic and diagnostic applications in immunology and oncology. PredictImmune develops prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated disorders.

Meanwhile, in its first product launch in mainland Europe, PredictImmune also has entered into a partnership with Theradiag, a France-based molecular diagnostics company. Under this agreement, Theradiag will have sole rights to promote, license, and distribute PredictSURE IBD to clinicians in France, Belgium, Luxembourg, and Switzerland, along with countries in Northwest Africa. Kinnon called the deal “another significant step” in marketing the diagnostics test worldwide.

“We are very pleased and honoured to have been chosen by PredictImmune for these specific missions across these five geographic areas,” Bertrand de Castelnau, Theradiag CEO, said in a press release about this agreement. “This partnership highlights our excellent knowledge of our markets, and we believe we are well positioned to help PredictImmune roll out its plan to develop its products abroad and specifically in these territories.”

A major step toward personalized medicine in IBD — a group of disorders that includes Crohn’s disease and ulcerative colitis — the blood-based test is based on a proprietary algorithm and a decade of extensive research into gene expression profiling of CD8+ T cells, a type of immune cell.

Developed in partnership with the University of Cambridge, PredictSURE IBD gives patients and healthcare professionals clear insight into the disease’s likely course — differentiating between an aggressive or relatively milder disease form — and more-informed therapeutic options at the point of diagnosis. With a better understanding of how the disease may affect individual patients, strategies such as lifestyle changes to enhance disease management can be discussed, implemented earlier, and monitored.

On the heels of a £10 million (about $12.8 million) fundraising effort, PredictImmune will offer its IBD test as both a laboratory test and as a kit, depending upon global market needs and requirements.

Results supporting the test were published in a study titled “A blood-based prognostic biomarker in IBD” in the journal Gut.

Characterized by chronic inflammation of the gastrointestinal tract, the autoimmune disease IBD affects some 10 million individuals worldwide.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 455
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • takeda research collaboration
  • CT-SCOUT app studied
  • gut microbes
  • Genedata

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?